Regeneron Pharmaceuticals Inc

Common Name
Regeneron Pharmaceuticals
Country
United States
Sector
Healthcare
Industry
Biotechnology
Employees
15,158
Ticker
REGN
Exchange
NASDAQ/NGS
Description
Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicines for serious medical conditions. The company's primary function is t...

Regeneron Pharmaceuticals's Climate Target Data Preview

As of 2023, Regeneron Pharmaceuticals has disclosed 1 climate targets aimed at reducing its greenhouse gas (GHG) emissions. These include 1 intensity-based target, signaling the company’s commitment to managing and lowering its carbon footprint over time. The targets span various emissions scopes and time horizons, offering insight into Regeneron Pharmaceuticals ’s climate strategy, ambition level, and alignment with global decarbonization goals.

Target TypeScope of TargetUnitTargetTarget Year
Intensity-based Target
Scope 1 - Total, Scope 2 - Total
Metric Tonnes of CO2 equivalent (mtCO2e) per Square Meter (m2)
Copy restricted. Please purchase to unlock this data.
2025

This table provides a simplified preview of selected climate targets data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.

Insights into Regeneron Pharmaceuticals's Greenhouse Gas Emissions Pathways

As of 2023, Regeneron Pharmaceuticals has set greenhouse gas (GHG) emissions reduction targets that cover its operational emissions (Scope 1 and 2), but not its value chain emissions (Scope 3). This means its reduction efforts currently focus on direct and purchased energy emissions.

Does Regeneron Pharmaceuticals have a target to reduce the emissions from its operations?

As of 2023, Regeneron Pharmaceuticals has set a target to reduce its operational greenhouse gas (GHG) emissions, specifically those from Scope 1 and Scope 2 sources.

Regeneron Pharmaceuticals's most ambitious operational target is to reduce these emissions by 30% by 2025, compared to a baseline of 0.379 Metric Tonnes of CO2 equivalent (mtCO2e) per Square Meter (m2) in 2016.

Regeneron Pharmaceuticals has already surpassed its operational emissions reduction target, with 2023 levels falling below the 2025 value, achieving its climate goal ahead of schedule.

Regeneron Pharmaceuticals's Operational (Scope 1+2) Emissions Pathway

20162023202500.10.190.290.38BaselineCurrent (-42%)Target 2025 (-30%)
Want Full Access to Regeneron Pharmaceuticals's Climate Targets Dataset?
Sign Up